(Q35870613)

10 August 2017

1 reference

title

Imatinib as a paradigm of targeted therapies (English)

1 reference

10 August 2017

1 reference

Brian J Druker

0 references

1 January 2004

1 reference

Advances in Cancer Research

10 August 2017

published in

1 reference

10 August 2017

1 reference

10 August 2017

page(s)

1-30

1 reference

High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia positive acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Unique forms of the abl tyrosine kinase distinguish Ph1-positive CML from Ph1-positive ALL

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL).

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Altered transcription of the c-abl oncogene in K-562 and other chronic myelogenous leukemia cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Activation of the c-abl oncogene by viral transduction or chromosomal translocation generates altered c-abl proteins with similar in vitro kinase properties

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Chronic myelogenous leukemia: biology and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Diagnosis of gastrointestinal stromal tumors: A consensus approach

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

An 8-kilobase abl RNA transcript in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

The story of chronic myeloid leukaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Treatment of hypereosinophilic syndrome with imatinib mesilate

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

PDGFRA activating mutations in gastrointestinal stromal tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Acute leukaemia in bcr/abl transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Unique fusion of bcr and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Reversibility of acute B-cell leukaemia induced by BCR-ABL1.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Protein-tyrosine kinases

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Favorable therapeutic index of a p210(BCR-ABL)-specific tyrosine kinase inhibitor; activity on lineage-committed and primitive chronic myelogenous leukemia progenitors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

The tyrosine kinase inhibitor STI571, like interferon-alpha, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Overlapping cDNA clones define the complete coding region for the P210c-abl gene product associated with chronic myelogenous leukemia cells containing the Philadelphia chromosome.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Mechanisms and implications of imatinib resistance mutations in BCR-ABL.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Fused transcript of abl and bcr genes in chronic myelogenous leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sa

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

The viral and cellular forms of the Abelson (abl) oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2804%2991001-9

7 January 2021

10.1016/S0065-230X(04)91001-9

Identifiers

DOI

0 references

1 reference